Month: March 2026

SEATTLE, March 18, 2026 (GLOBE NEWSWIRE) — Banzai International, Inc. (NASDAQ: BNZI) (“Banzai” or the “Company”), a leading AI-powered sales & marketing technology company, will hold a conference call on Tuesday, March 31, 2026, at 4:30 p.m. Eastern Time to discuss its financial results for the fourth quarter ended December 31, 2025, as well as review ongoing initiatives and anticipated milestones. Banzai Founder & CEO Joe Davy and CFO Dean Ditto will host the conference call, followed by a question-and-answer session. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of the Company’s website here. To access the call, please use the following information:Date: Tuesday, March 31, 2026Time: 4:30 p.m. Eastern Time (1:30 p.m....

SUNNYVALE, Calif., March 18, 2026 (GLOBE NEWSWIRE) — GSI Technology, Inc. (Nasdaq: GSIT) today announced that its Board of Directors has concluded the Company’s previously announced review of strategic alternatives. In reaching this determination, the Board considered the Company’s operational and financial progress and the strengthened balance sheet following the October 2025 capital raise, which provided additional resources to support GSI Technology’s go-forward plan. As part of the review, the Board and its advisors engaged with multiple parties and evaluated a range of potential alternatives. After careful consideration, the Board concluded that continuing to execute the Company’s standalone strategy is in the best interests of stockholders at this time. The Company intends to focus on driving commercialization of its high-performance...

Brain-derived, fully automated Atellica IM Phosphorylated tau 217 (pTau217) and Atellica IM Brain Derived Tau (BDTau) assays now available for research useBrain ImageSiemens Healthineers announced today its offerings for brain health research are expanding, with the brain-derived, fully automated Atellica IM Phosphorylated tau 217 (pTau217) and Atellica IM Brain Derived Tau (BDTau) assays now available for research use.Tarrytown, New York, USA, March 18, 2026 (GLOBE NEWSWIRE) —Research assays help generate evidence about whether biomarkers can advance disease management Novel RUO tests can help scientists understand neurological function and disease progression Collaborative research is underway to translate scientific discovery into actionable evidenceSiemens Healthineers announced today its offerings for brain health...

Strengthens footprint in high-volume Chesapeake Bay market Adds 150 boat storage capacity, reducing third-party costs Enhances inventory sourcing, reconditioning, and transaction efficiency Wilmington, NC, March 18, 2026 (GLOBE NEWSWIRE) — Off The Hook YS Inc. (NYSE American: OTH) (“Off the Hook Yachts” or “Off the Hook” or “the Company”), a vertically integrated, AI-powered marine marketplace and the largest buyer and seller of used boats in the nation, today announced the acquisition of a strategic waterfront property on the Chesapeake Bay, one of the most active boating corridors in the United States. The acquisition will serve as the Company’s new Mid-Atlantic operational hub in a high-density marine market while expanding capabilities for inventory reconditioning, storage, financing, and asset recovery. “The Piney Narrows location...

Company surpasses milestone of 150 cumulative telesurgeries successfully performed with the SSi Mantra FORT LAUDERDALE, Fla., March 18, 2026 (GLOBE NEWSWIRE) — SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company’s SSi Mantra surgical robotic system has been approved for telesurgeries in Indonesia and the Philippines. The Company today also announced that more than 150 cumulative telesurgeries have been successfully performed utilizing the SSi Mantra surgical robotic system, primarily in India. Among recent highlights showcasing the advanced capabilities of the SSi Mantra, a total of 18 inter-hospital telesurgeries were performed...

Company to host conference call to discuss financial results and provide a corporate update on March 25, 2026 at 4:30 p.m. ET SCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) — Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its year end 2025 financial results after the U.S. financial markets close on Wednesday, March 25, 2026. Journey Medical management will conduct a conference call and audio webcast on Wednesday, March 25, 2026 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509...

Incline Village, NV, March 18, 2026 (GLOBE NEWSWIRE) — Mountain Lake Acquisition Corp. II (Nasdaq: MLAAU) (the “Company”) announced today that, commencing March 19, 2026, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The Class A ordinary shares and warrants that are separated will trade on the Nasdaq Global Market under the symbols “MLAA” and “MLAAW,” respectively. Those units not separated will continue to trade on the Nasdaq Global Market under the symbol “MLAAU.” This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there...

LA JOLLA, Calif., March 18, 2026 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 38th Annual Roth Conference for Growth Companies on Monday, March 23, 2026 at 8:30am PT. Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference. About EquilliumEquillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company’s lead therapeutic candidate is EQ504, a potent and selective aryl hydrocarbon receptor modulator designed with a multi-modal, non-immunosuppressive mechanism of action to be complementary to...

TOMI Capitalizes on Global Food Safety Demand FREDERICK, Md., March 18, 2026 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, is accelerating its expansion into the food safety sector by delivering unprecedented operational savings of up to 95%. As global supply chains face mounting pressure to eliminate pathogens such as Salmonella, Listeria, and E. coli, the industry is rapidly transitioning from legacy chemical applications toward the advanced, science-driven efficacy of SteraMist ionized Hydrogen Peroxide (iHP) technology. The financial stakes for food safety have never been higher, with industry data indicating that the average direct cost of a single food recall now reaches nearly $10 million when accounting for notification, product...